These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7731489)

  • 1. Heparin-induced thrombocytopenia and thrombosis: a potential fatal complication in a routine treatment.
    Boon DM; Kappers-Klunne MC; Michiels JJ; Stibbe J; van Vliet HH
    Neth J Med; 1995 Mar; 46(3):146-52. PubMed ID: 7731489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
    Ranze O; Ranze P; Magnani HN; Greinacher A
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of low dose Orgaran in heparin-induced thrombocytopenia associated with in vitro platelet aggregation at higher Orgaran concentrations.
    Hill GR; Hickton C; Henderson S; Patton WN
    Clin Lab Haematol; 1997 Jun; 19(2):155-7. PubMed ID: 9218159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
    Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful use of a heparinoid (danaparoid sodium) for heparin-induced thrombocytopenia type II in aortic valve reoperation].
    Scheffler E; Aulmann M; Remppis A; Ziegler R; Martin E; Fleischer F; Nawroth P
    Z Kardiol; 1995 Jul; 84(7):565-8. PubMed ID: 7676727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S; Manhas AH; Udden M; Rice L
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
    Zöhrer' B; Zenz W; Rettenbacher A; Covi P; Kurnik K; Kroll H; Grubbauer HM; Muntean W
    Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
    Hale LP; Smith K; Braden GA; Owen J
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):318-22. PubMed ID: 9829897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Danaparoid (orgaran) for continuous venovenous hemodiafiltration in a patient with heparin-induced thrombocytopenia].
    Christin F; Theissen-Laval O; Loeb JP
    Ann Fr Anesth Reanim; 1998; 17(1):82-3. PubMed ID: 9750692
    [No Abstract]   [Full Text] [Related]  

  • 14. [Heparin-induced thrombopenia and thrombosis].
    Stöckli TC; Walther A; Görres G; Ritz R; Marbet GA
    Schweiz Med Wochenschr; 1996 Mar; 126(12):483-8. PubMed ID: 8650513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-induced thrombocytopaenia complicated by arterial and venous thrombosis: report of 2 cases successfully treated by a danaparoid sodium.
    Darling K; Jaumotte C; Saussoy P; Zech F; Lavenne E; Hainaut P
    Acta Clin Belg; 2000; 55(3):176-81. PubMed ID: 10981327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
    Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
    Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).
    Saxon BR; Black MD; Edgell D; Noel D; Leaker MT
    Ann Thorac Surg; 1999 Sep; 68(3):1076-8. PubMed ID: 10510017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lepirudin use in a neonate with heparin-induced thrombocytopenia.
    Nguyen TN; Gal P; Ransom JL; Carlos R
    Ann Pharmacother; 2003 Feb; 37(2):229-33. PubMed ID: 12549954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.